Alchemia Achieves $3.4 Million Quarterly Fondaparinux Profit Share

Alchemia Achieves $3.4 Million Quarterly Fondaparinux Profit Share 
BRISBANE, AUSTRALIA -- (Marketwire) -- 02/18/13 -- 

--  profit share up over 90% on last quarter
--  market share increased to 25% from 22%
--  cost of goods significantly improved

Alchemia Limited (ASX: ACL) has recorded a quarterly profit share of
$3.4 million on sales of its generic anti-coagulant product
fondaparinux, an increase of over 90% from the previous quarter. 
The profit share results from total net sales of $12.3 million. The
funds owing to Alchemia Limited will be US$2.9m following the
contribution of $0.5m by Alchemia to the agreed activities to improve
yields and cost of goods as previously disclosed. 
Fondaparinux was launched in the US by the company's worldwide
marketing partner Dr Reddy's Laboratories, Inc (DRL) in July 2011 and
is an FDA approved generic version of Arixtra(TM), marketed by
GlaxoSmithKline plc. 
Dr Reddy's average market share for the quarter ending 31 December
2012 was 25%, compared with 22% for the quarter ending 30 September
2012. (Source: IMS). 
Alchemia CEO Charlie Walker said: "It is pleasing to see a
significant improvement in profits this quarter compared with the
last quarter. This is mainly a result of the joint investment in
process improvement and reduction in the cost of the API. We look
forward to updating the market on next quarter's profit share." 
About Alchemia Limited: 
 Alchemia is a drug development company with
late stage oncology product pipeline (Phase II and III), and an FDA
approved drug (Fondaparinux). 
Fondaparinux (a generic version of GlaxoSmithKline's Arixtra(R)) is
an injectable anticoagulant approved in the US for the prevention and
treatment of deep vein thrombosis (DVT) after knee or hip surgery.
The ANDA for generic fondaparinux was approved by the US FDA in July
2011 and launched in the US by marketing partner Dr Reddy's
Laboratories. Alchemia received its first profits from sales of
fondaparinux in August 2011.  
Alchemia's pipeline of oncology products is built on the proprietary
platform technology: HyACT(R) (targeted cancer delivery), which is
used to selectively target cancer drugs to tumours. The primary
objective of the HyACT(R) technology is to develop a new generation
of anti-c
ancer drugs which demonstrate better efficacy. The Company
has recently announced the final recruitment for its most advance
cancer drug -- HA-Irinotecan which is in Phase III for the treatment
of metastatic colorectal cancer. 
In addition, Alchemia has a platform technology, VAST(R), discovery
drug discovery platform, which is based on Alchemia's chemistry
expertise. VAST is run on a business model designed to limit use of
cash expenditure through the use of partnerships and government
grants. The company has projects running with academic institutions
and evaluation underway with big pharma partners. 
For further information: 
Dr Mel Bridges
Alchemia Limited
Mobile/Cell: +61 4 1305 1600 
Charles Walker
Chief Executive Officer
Alchemia Limited 
Tel: +61 7 3340 0200 
Media enquiries, Australia:
Emma Power or Rudi Michelson
Monsoon Communications 
+613 9620 3333 
Investor Relations USA:
Laura Forman
Blueprint Life Science Group 
+1 415 375 3340 Ext. 103 
Press spacebar to pause and continue. Press esc to stop.